The role of dihydrotestosterone in benign prostatic hyperplasia

This publication has 14 references indexed in Scilit:

• Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
  Urology, 2002
• Proliferation and differentiation of prostatic stromal cells
  BJU International, 2001
• Androgen receptor signalling in the prostate
  BJU International, 2000
• Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue
  The Journal of Steroid Biochemistry and Molecular Biology, 1999
• Endocrine and adrenergic pharmacological intervention in diseasesof the prostate
  British Journal of Clinical Pharmacology, 1998
• The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
  New England Journal of Medicine, 1998
• Modulation of Sensitivity to Transforming Growth Factor-β1 (TGF-β1) and the Level of Type II TGF-β Receptor in LNCaP Cells by Dihydrotestosterone
  Experimental Cell Research, 1996
• Testosterone at High Concentrations Interacts with the Human Androgen Receptor Similarly to Dihydrotestosterone*
  Endocrinology, 1990
• Antagonistic effect of androgen on prostatic cell death
  The Prostate, 1984
• Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male Pseudohermaphroditism
  Science, 1974